Level C· Early human research exploring benefitsProspective StudyPubMed

Diabetes impairs the angiogenic capacity of human adipose-derived stem cells by reducing the CD271 + subpopulation in adipose tissue.

Inoue O., Usui S., Takashima SI., Nomura A., Yamaguchi K., Takeda Y.

Prospective Study on Type 2 Diabetes, published in Biochem Biophys Res Commun (2019) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Biochem Biophys Res Commun (2019)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
31362891
DOI
10.1016/j.bbrc.2019.07.081
Citations
23

Abstract (original English)

Type 2 diabetes mellitus is an important risk factor for cardiovascular diseases (CVDs). Therapeutic angiogenesis using adipose-derived stem cells (ADSCs) is attractive for CVD therapy. However, although it would be critical for ADSC application on CVD therapy, whether and how diabetes impairs human ADSC therapeutic potential is still uncertain. In this study, we aimed to investigate the impact of diabetes on the angiogenic potential of ADSCs in patients with CVDs, with special focus on stemness-related genes and cellular alteration of ADSCs. We established cultured ADSCs from diabetic (DM-ADSCs) and non-diabetic patients (nonDM-ADSCs) with CVDs. DM-ADSCs demonstrated limited proliferative capacity and reduced paracrine capacity of VEGF, with lower expression of the stemness gene SOX2. Angiogenic capacity and ADSC engraftment were assessed using xenograft experiments in a hindlimb ischemia model of athymic nude mice. Consistent with the results of in vitro assays, DM-ADSCs did not rescue limb ischemia. In contrast, nonDM-ADSCs induced neovascularization with enhanced engraftment. To elucidate the mechanism underlying these ADSC changes, we compared the surface marker profiles of freshly isolated ADSCs obtained from diabetic and non-diabetic patients by flow cytometry. Among studied subsets, the CD34 + CD31 - CD271 + subpopulation was reduced in the adipose tissues of diabetic p

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdapaleneAdipose TissueAnimalsCell ProliferationCells, CulturedDiabetes MellitusFemaleHumansMaleMice, Nude

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research